Naji Khairallah
Internal Medicine · Paw Paw, MINPI 1710963970
Payments from drug & device makers
Across 96 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$331
- Pfizer$227
- Lilly USA, LLC$209
- Boehringer Ingelheim$197
- Novo Nordisk$112
- AbbVie$88
- plus $733 from 23 others
What the payments were for
- Food & beverage$1,897100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $331 |
| Pfizer | 13 | $227 |
| Lilly USA, LLC | 8 | $209 |
| Boehringer Ingelheim | 8 | $197 |
| Novo Nordisk | 8 | $112 |
| AbbVie | 5 | $88 |
| GSK | 5 | $72 |
| Merck | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Lundbeck LLC | 2 | $48 |
| Dexcom, Inc. | 2 | $40 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Abbott | 2 | $38 |
| Mylan Specialty L.p. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $36 |
| Organon | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $34 |
| Amgen | 2 | $32 |
| Novartis | 2 | $30 |
| Johnson & Johnson | 2 | $25 |
| Genentech USA, Inc. | 1 | $21 |
| Viiv Healthcare Company | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Corium, LLC | 1 | $17 |
| Cranial Technologies, Inc | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
How this compares
$1,897 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 126 | $96,301 |
| TrulicityDulaglutide | 74 | $81,383 |
| JardianceEmpagliflozin | 103 | $76,281 |
| OzempicSemaglutide | 33 | $39,758 |
| XareltoRivaroxaban | 39 | $36,562 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $31,749 |
| MounjaroTirzepatide | 30 | $31,619 |
| MyrbetriqMirabegron | 53 | $24,700 |
| Spiriva RespimatTiotropium Bromide | 16 | $15,544 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $12,372 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $11,818 |
| Bydureon BciseExenatide Microspheres | 13 | $10,793 |
| RybelsusSemaglutide | 12 | $10,577 |
| Xtampza ErOxycodone Myristate | 13 | $9,120 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 397 | $9,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $209 | $113,002104 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $197 | $99,024134 claims |
| PfizerEliquis, Premarin | $227 | $98,938139 claims |
| Novo NordiskOzempic, Rybelsus | $112 | $50,33545 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $72 | $38,02562 claims |
| Johnson & JohnsonXarelto | $25 | $36,56239 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $24,70053 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $331 | $22,39743 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $14 | $9,12013 claims |
| MerckJanuvia | $60 | $6,09111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Paw Paw
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.